30 September 2009
Effect of beta blockers on sepsis outcome
Jose GutierrezABDEFG, Amin HossamA, Roxana LazarezcuB, El KayB, Tatjana RundekCDEMed Sci Monit 2009; 15(10): CR499-503 :: ID: 878210
Abstract
Background
The aim of this study was to investigate weather beta blockers are associated with an increased mortality in sepsis.
Material and Method
Data on 83 patients with sepsis treated in ICU were analyzed from the retrospective chart review. The association between treatment with Beta blockers and mortality was analyzed by logistic regression in univariate model and after adjusting for the APACHE morbidity/ mortality scores.
Results
Among 83 patients (mean age 56.2+/-17.3 years, female 51%, the mean APACHE score 74.8+/-23.3), 29 were treated with BB. Those treated with BB had APACHE score of 79.93+/-23.47 and those not treated with BB had APACHE score of 73.67+/-23.21. No significant difference between the traditional cardiovascular risk factors was found in both groups except for HTN. Treatment with BB was not significantly associated with mortality in the univariate (OR=1.83, 95% CI 0.59-5.69) nor multivariate model (OR=1.843, 95% CI 0.56-6.10). The APACHE score was a strong predictor of mortality (OR=1.04, 95% CI 1.01-1.06, p=0.02). This association was independent of BB use, and no significant interaction (p=0.72) between BB and APACHE score was observed.
Conclusions
We did not show a significant association between beta blockers and increased mortality in patients with sepsis. Sicker patients had an increase risk of death, and possibility that beta blocker use may have contributed to this risk cannot be completely ruled out. Our study was limited by a small sample size and retrospective design. Further investigations of potential benefits and side effect of beta blockers in patients with sepsis are warranted.
Keywords: Sepsis - drug therapy, Aged, 80 and over, Adrenergic beta-Antagonists - therapeutic use, APACHE, young adult
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952